Scarica l'app Stockscreener
13.31
0.23%
0.03
Dopo l'orario di chiusura:
13.09
-0.22
-1.65%
Aardvark Therapeutics Inc Borsa (AARD) Ultime notizie
What AI ML Trends Might Elevate Advance Metering Technology Limiteds Stock ProspectsLong-Term Growth Stocks & Free Unstoppable Trading Performance - earlytimes.in
Aug Gainers: Will Aardvark Therapeutics Inc stock deliver consistent dividends2025 Momentum Check & Community Trade Idea Sharing Platform - moha.gov.vn
Aardvark Therapeutics prices $94M IPO at $16 per share - MSN
Critical Contrast: Aardvark Therapeutics (AARD) and The Competition - Defense World
Aardvark Therapeutics up 9% at $10.10 after Raymond James Strong Buy initiation - MSN
Aardvark Therapeutics (AARD) – Investment Analysts’ Recent Ratings Updates - Defense World
Aardvark Therapeutics initiated with an outperform at Oppenheimer - MSN
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating - Investing.com India
Oppenheimer Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) added to NASDAQ Biotechnology Index - marketscreener.com
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Is Aardvark Therapeutics Inc. stock attractive for hedge fundsTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - bolumsonucanavari.com
What risks investors should watch in Aardvark Therapeutics Inc. stockMarket Risk Report & AI Forecast for Swing Trade Picks - Улправда
Will Aardvark Therapeutics Inc. stock maintain dividend yieldJuly 2025 Sector Moves & Smart Money Movement Tracker - DonanımHaber
Can Aardvark Therapeutics Inc. stock attract ESG capital inflows2025 Market Trends & Fast Moving Stock Trade Plans - DonanımHaber
How resilient is Aardvark Therapeutics Inc. stock in market downturns2025 Market Sentiment & Technical Pattern Based Signals - Улправда
Insider Buying: Aardvark Therapeutics CEO, Secretary & Director Bought US$101k Of Shares - simplywall.st
HC Wainwright Has Negative Outlook for AARD FY2025 Earnings - Defense World
Aardvark Therapeutics (NASDAQ:AARD) CEO Tien-Li Lee Purchases 7,000 Shares - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) CFO Purchases $43,200.00 in Stock - MarketBeat
Insider Stock Purchases: December 13, 2025 - Quiver Quantitative
Analysts’ Top Healthcare Picks: Aardvark Therapeutics, Inc. (AARD), Eli Lilly & Co (LLY) - The Globe and Mail
William Blair initiates coverage on Aardvark Therapeutics stock with Outperform rating - Investing.com Canada
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 By Investing.com - Investing.com Nigeria
Insider Buying: Nelson Sun Acquires Additional Shares of Aardvar - GuruFocus
Lee Tien-Li, CEO of Aardvark, buys $101k in AARD stock - Investing.com Australia
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 - Investing.com
Aardvark Therapeutics Executives Increase Their Holdings - TradingView — Track All Markets
CFO Sun Buys 3,000 ($43.2K) Of Aardvark Therapeutics Inc [AARD] - TradingView — Track All Markets
William Blair Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst - Sahm
William Blair Initiates Aardvark Therapeutics With Outperform Rating - marketscreener.com
Aardvark Therapeutics: Innovative Therapies for PWS and Obesity with Significant Market Potential - TipRanks
Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy By Investing.com - Investing.com South Africa
Aardvark Therapeutics’ Promising Progress and Market Potential: Analyst Recommends Buy - TipRanks
Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy - Investing.com Canada
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target - Investing.com Nigeria
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target By Investing.com - Investing.com South Africa
Aardvark doses first Australian patient in phase 3 PWS hunger trial - Investing.com Nigeria
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):